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Abstract
 
Neonatal islet-specific expression of tumor necrosis factor (TNF)-
 
a 
 
in nonobese diabetic mice
promotes diabetes by provoking islet-infiltrating antigen-presenting cells to present islet peptides
to autoreactive T cells. Here we show that TNF-
 
a
 
 promotes autoaggression of both effector
 
CD4
 
1
 
 and CD8
 
1
 
 T cells. Whereas CD8
 
1
 
 T cells are critical for diabetes progression, CD4
 
1
 
 T
cells play a lesser role. TNF-
 
a
 
–mediated diabetes development was not dependent on CD154–
CD40 signals or activated CD4
 
1
 
 T cells. Instead, it appears that TNF-
 
a
 
 can promote cross-pre-
sentation of islet antigen to CD8
 
1
 
 T cells using a unique CD40–CD154-independent pathway.
These data provide new insights into the mechanisms by which inflammatory stimuli can bypass
CD154–CD40 immune regulatory signals and cause activation of autoreactive T cells.
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Introduction
 
The differentiation of naive CD8
 
1
 
 T cells into effector CTLs
normally requires the interaction of three types of cells:
APCs bearing peptide–MHC complexes, CD4
 
1
 
 T cells, and
CD8
 
1
 
 T cells. Until recently, our understanding of the im-
portance of CD4
 
1
 
 T cells in this three-cell interaction was
to provide “help” directly to the naive CD8
 
1
 
 T cell, e.g.,
by the secretion of lymphokines like IFN-
 
g
 
 (1). Now, how-
ever, three reports have demonstrated that CD4
 
1
 
 T cell
help for the differentiation of naive CD8
 
1
 
 T cells into ef-
fector CTLs is at the level of the APC (2–4), where initial
engagement of CD4
 
1
 
 T cells with APCs triggers the matu-
ration of the APC into a cell fully competent to prime
CD8
 
1
 
 T cells.
Deciphering these molecular interactions between CD4
 
1
 
T cells and APCs involved in the generation of humoral and
cell-mediated immunity has advanced remarkably (5–7). In
particular, interactions between CD40 on APCs and CD154
on activated CD4
 
1
 
 T cells play a dominant role in the gen-
eration of T and B cell immunity (for review see reference
8). CD40–CD154 signals enhance APC activity by upreg-
ulating adhesion and costimulatory molecules (9), as well as
generating antiapoptotic signals that increase APC survival
(10) and thus prolong contact between APCs and T cells.
The importance of CD40–CD154 signals in the generation
of efficient T cell immunity is exemplified by the finding
that cross-linking of CD40 on APCs can bypass the need for
CD4
 
1
 
 T cells in the differentiation of naive CD8
 
1
 
 T cells
into effector CTLs (3). Indeed, blockade of CD40–CD154
interactions with antisera, or the absence of a functional
CD40 or CD154 gene, leads to impaired humoral responses
to thymus-dependent antigens (11–13) by preventing effi-
cient activation of APCs (8). Several autoimmune conditions
have been shown to be dependent on CD40–CD154 signals
(13–15), and in diabetes, blockade of CD40–CD154 signals
abrogates both insulitis and diabetes (14).
In insulin-dependent autoimmune diabetes, where insulin-
producing 
 
b
 
 cells in the islets of Langerhans are destroyed
by T cell–mediated mechanisms (for review see reference
16), the importance of CD4
 
1
 
 and CD8
 
1
 
 T cells for 
 
b
 
 cell
destruction has been strongly debated. For example, several
reports in nonobese diabetic (NOD)
 
1
 
 mice that spontane-
ously develop diabetes have shown that deficiency in 
 
b
 
2
 
-
microglobulin (and, as a consequence, CD8
 
1
 
 T cells) or
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treatment with anti-CD8 antibodies from birth protects
from disease (17–20). Similarly, NOD mice treated with
anti-CD4 antibodies or NOD mice deficient in CD4
 
1
 
 T
cells do not develop diabetes (21, 22). These reports suggest
a requirement for both CD4
 
1
 
 and CD8
 
1
 
 T cells in insulin-
dependent autoimmune diabetes, which has been substan-
tiated by adoptive transfer experiments (23, 24). The dual
role for CD4
 
1
 
 and CD8
 
1
 
 T cells is believed to relate in part
to the requirement for CD4
 
1
 
 T cell help in the generation of
 
b
 
 cell–specific CD8
 
1
 
 CTLs (21). This suggests that diabetes
development in NOD mice involves the cross-presentation
(25) of exogenous islet antigen to naive islet-specific CD8
 
1
 
T cells.
Inflammatory cytokines have been implicated in the break-
down of tolerance of self-reactive T cells to host tissue and
subsequent autoimmunity (26), although the mechanisms
responsible remain elusive. In particular, there has been a
strong association between the inflammatory cytokine TNF-
 
a
 
and the development of diabetes in NOD mice. This has
been based on studies demonstrating that (a) TNF-
 
a
 
 mRNA
is produced in inflamed islets in NOD mice (27) and (b)
systemic administration of TNF-
 
a
 
 in neonatal NOD mice
accelerates diabetes progression, whereas (c) neutralization
of TNF-
 
a
 
 in neonatal NOD mice protects against disease
(28). Recently, we demonstrated that localized, islet-spe-
cific expression of TNF-
 
a
 
 in neonatal NOD (TNF-
 
a
 
–NOD)
mice was sufficient to accelerate diabetes onset. This rapid
 
progression to diabetes was preceded by apoptosis of some
 
b
 
 cells, followed by TNF-
 
a
 
–mediated recruitment of APCs,
particularly dendritic cells (DCs), and T cells to neonatal is-
lets and a subsequent enhancement in the presentation of
islet antigen to autoreactive T cells in situ (29). However,
the requirement for CD4
 
1
 
 and CD8
 
1
 
 T cells in this accel-
erated model of diabetes was unknown.
In this article, we show that TNF-
 
a
 
 enhances autoim-
munity in NOD mice by provoking islet-infiltrating APCs
to cross-present exogenous islet antigen to CD8
 
1
 
 T cells.
Furthermore, using a series of knockout models, we estab-
lish that effector CD4
 
1
 
 T cells are not required for the
priming of islet-specific CD8
 
1
 
 T cells. Indeed, we provide
strong evidence that TNF-
 
a
 
 can substitute for CD4
 
1
 
 T cell
help in the cross-presentation of exogenous islet antigen to
CD8
 
1
 
 T cells by overcoming the need for CD154 signals
in the activation of islet-infiltrating APCs. These findings
reveal that inflammatory stimuli may promote autoimmu-
nity by thwarting normal CD4
 
1
 
 T cell–dependent CD154
immune regulatory mechanisms.
 
Materials and Methods
 
Mice.
 
All knockout and transgenic mice used in this study are
on the NOD background and are described in Table I. TNF-
 
a
 
–
NOD mice and NOD mice deficient for 
 
b
 
2
 
-microglobulin (NOD–
 
b
 
2
 
m
 
2
 
/
 
2
 
) have been described previously (18, 20, 29).
 
Table I.
 
Classification of the Transgenic and Knockout Models Used in This Study
 
Mouse Phenotype Insulitis Diabetes Reference no.
TNF-
 
a
 
–NOD Transgenic expression of
TNF-
 
a
 
 in islets yes yes 29
NOD–
 
b
 
2
 
m
 
2
 
/
 
2
 
No MHC class I;
few CD8
 
1
 
 T cells no no 18, 20
TNF-
 
a
 
–
 
b
 
2
 
m
 
2
 
/
 
2
 
No MHC class I;
few CD8
 
1
 
 T cells;
transgenic expression of
TNF-
 
a 
 
in islets yes no This study
NOD–CIITA
 
2
 
/
 
2
 
No MHC class II
on APCs; yes no 21
few CD4
 
1
 
 T cells (periinsulitis)
TNF-
 
a
 
–CIITA
 
2
 
/
 
2
 
No MHC class II
on APCs;
few CD4
 
1
 
 T cells;
transgenic expression of
TNF-
 
a 
 
in islets yes yes This study
NOD–CD154
 
2
 
/
 
2
 
No CD154 on T cells no no This study
TNF-
 
a
 
–CD154
 
2
 
/
 
2
 
No CD154 on T cells;
transgenic expression of
TNF-
 
a 
 
in islets yes yes This study
The phenotypes of all of the transgenic and knockout NOD models used in this study and their ability to progress to diabetes.
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TNF-
 
a
 
–
 
b
 
2
 
m
 
2
 
/
 
2
 
 mice were generated by crossing N10 TNF-
 
a
 
–NOD mice to N10 NOD–
 
b
 
2
 
m
 
2
 
/
 
2
 
 mice. TNF-
 
a
 
1
 
 progeny were
detected by PCR (29) and further screened for the presence of
the 
 
b2m null mutation by measuring CD81 T cell numbers and
assessing for MHC class I H2-Kd and H2-Db molecules on im-
mune cells in the peripheral blood. TNF-a–MHC class II
transactivator2/2 (TNF-a–CITA2/2) mice were generated by
crossing N11 TNF-a–NOD mice to N11 NOD–CIITA2/2
mice (21). TNF-a–CIITA2/2 mice were detected by Southern
blot analysis as previously described (30).
TNF-a–CD1542/2 mice were generated by crossing N11 TNF-
a–NOD mice with N11 NOD–CD1542/2 mice and then inter-
crossing heterozygous populations. All mice were screened for
the presence of CD154 by PCR combining primer sequences
that detected the wild-type gene (59 fi 39 CCC AAG TGT ATG
AGC ATG TGT GT and GTT CCT CCA CCT AGT CAT
TCA TC) and the neo cassette (59 fi 39 GCC CTG AAT GAA
CTG CAG GAC G; CAC GGG TAG CCA ACG CTA TGT C).
Cycling conditions were 30 cycles of 948C for 45 s, 578C for 1 min,
and 728C for 1 min. The CD41 islet-specific TCR-transgenic
mice, BDC2.5 on the NOD background, have been described
elsewhere (31) and were provided by J.D. Katz (Washington
University, St. Louis, MO). All NOD mice used for breeding
and experimental purposes were bred and maintained in our ani-
mal facility, the disease incidence in the colony being 80% for fe-
males and 50% for males by 30 wk of age.
Adoptive Transfers. Whole splenocytes were isolated from 6-wk-
old BDC2.5 CD41 TCR-transgenic mice, and RBCs were lysed
by H2O treatment. Splenocytes were washed twice in Bruff’s me-
dium supplemented with 5% FBS (Bruff/5) and then once in
sterile saline. For the islet-reactive CD81 T cell clone TGNFC8,
the cells were removed from culture and washed twice in sterile
saline. In both cases, the cells were resuspended in sterile saline
and injected into the retroorbital vein at a concentration of 107
cells per mouse.
Isolation of Cells. Islets were isolated after collagenase (Boeh-
ringer Mannheim) digestion of pancreata. The infiltrating cells
were liberated by trypsinization and washed three times in RPMI
medium supplemented with 5% FBS (RPMI/FBS). CD41 and
CD81 T cells were isolated from either the pancreatic lymph
node or spleen by crushing the tissue through nylon mesh. The
RBCs were removed with Tris-buffered NH4Cl, and the re-
maining white blood cells were washed three times in RPMI/
FBS. For purification of CD41 T cells, the cell suspension was
incubated with unlabeled rat anti-CD8 (53-6.72) antibodies, fol-
lowed by incubation with goat anti–rat IgG (H1L chain) and
goat anti–mouse IgG (H1L chain) BioMag® beads (both from
PerSeptive Biosystems). Macrophages (MFs) and DCs were sub-
sequently removed by incubation on plastic at 378C for 45 min.
Purity of the CD41 T cell population was verified by FACS®
analysis. For purification of CD81 T cells, the cell suspension was
incubated with unlabeled rat anti-CD4 (GK1.5) antibodies, fol-
lowed by incubation with goat anti–rat IgG (H1L chain) and
goat anti–mouse IgG (H1L chain) BioMag® beads. MFs and
DCs were subsequently removed as above. Again, purity of the
CD81 T cell population was verified by FACS® analysis.
FACS® Analysis. All antibodies used for FACS® analysis were
obtained from PharMingen. The cells under analysis were pre-
pared as described above and then washed twice in FACS buffer
(PBS containing 2% FBS). The cells were incubated with the ap-
propriate fluorochrome-labeled antibody for 30 min at 48C. After
three successive washings in FACS buffer, the cells were analyzed
using FACSCalibur™ (Becton Dickinson).
For measurement of intracellular perforin, after addition of fluo-
rochrome-labeled antibodies to extracellular proteins, the cells were
fixed in 1% paraformaldehyde for 30 min at 48C. After two succes-
sive washes in FACS buffer, fixed cells were incubated with bio-
tinylated rat anti–mouse perforin antibody (PharMingen) or isotype
control antibody (PharMingen) diluted in PBS supplemented with
2% FBS and 0.03% saponin (PBS/saponin) for 30 min at 48C. The
cells were washed twice in FACS buffer and then incubated with
fluorochrome-labeled streptavidin in PBS/saponin buffer for 30
min at 48C, after which the cells were washed three times in FACS
buffer and analyzed as described above.
Immunizations and Measurement of Anti–Keyhole Limpet Hemag-
glutinin Responses. Keyhole limpet hemagglutinin (KLH; Calbio-
chem-Novabiochem Corp.) was emulsified in alum and injected
into the footpads of 5-wk-old mice at 100 mg per mouse. 7 d af-
ter immunization, the popliteal lymph nodes were removed and
the cells isolated as described above. 5 3 105 cells were stimulated
with KLH at the concentrations described in the text. After incu-
bation at 378C in 5% CO2 for 4 d and a 21-h pulse with 1 mCi/
well [3H]thymidine (Amersham Pharmacia Biotech Inc.) on the
last day of the culture, cells were harvested and [3H]thymidine in-
corporation was measured.
Measurement of Glutamic Acid Decarboxylase Responses. Responder
CD41 T cells were purified as described above. As a source of APCs,
6-wk-old NOD mice were killed, and after removal of red blood
cells, total splenocyte populations were irradiated (3,000 rads).
Unless otherwise stated in the text, 3 3 105 purified CD41 T cells
were incubated with 5 3 103 irradiated splenocytes, and 0–20 mg/
ml of glutamic acid decarboxylase (GAD)p35 (amino acids 524–543)
was added to the assay. After incubation at 378C in 5% CO2 for 4 d
and a 14-h pulse with 1 mCi [3H]thymidine (Amersham) on the
last day of culture, cells were harvested and [3H]thymidine incor-
poration was measured.
Antigen Presentation Assays. The ability of islet-infiltrating cells
to present islet antigen to responder CD41 and CD81 T cells was
assessed as previously described (29). In brief, islet-infiltrating
cells to be used as a source of APCs in the assays were isolated by
collagenase digestion of pancreata followed by trypsinization and
then irradiated (4,000 rads). Responder CD41 or CD81 T cells
were purified as before. Unless otherwise stated, 5 3 104 irradi-
ated islet-derived cells were incubated with 105 purified CD41 or
CD81 T cells for 4 d at 378C in 5% CO2. The cells were pulsed
with 1 mCi [3H]thymidine for the last 16 h of the assay, and pro-
liferative responses were measured as above.
Measurement of IL-4 and IFN-g. Islet-infiltrating cells were lib-
erated from islets as described above. CD81 T cells were re-
moved by magnetic bead separation techniques. The remaining
islet cells, including APCs and CD41 T cells, were incubated for
48 h in the presence of 2.5 mg/ml of Con A, after which the cul-
ture supernatants were harvested for measurement of IL-4 and
IFN-g concentrations using cytokine-specific ELISAs. In brief,
Maxisorp Nunc-immuno plates (Nalge Nunc International) were
coated with purified rat anti–IL-4 or anti–IFN-g antibodies (Phar-
Mingen) in carbonate buffer, pH 9.6, overnight at 48C. After block-
ing in PBS containing 3% FBS, supernatants or standard controls
were added and allowed to incubate overnight at 48C. Bound IL-4
or IFN-g was visualized by incubation with biotinylated rat anti–
IL-4 or IFN-g, respectively (PharMingen), followed by horserad-
ish peroxidase–labeled streptavidin (Vector Labs., Inc.) and TMB
substrate (Kirkegaard & Perry Labs., Inc.). The concentrations of
IL-4 and IFN-g were calculated using the Microplate Manager
III program (Bio-Rad Labs.).
Diabetes Detection. Mice were tested once weekly for glycos-
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uria using Diastix® reagent strips for urinalysis (Ames Co.) start-
ing at 4 wk of age. Diabetes was confirmed when nonfasting
glucose values in the serum were higher than 250 mg/dl, as de-
termined by One Touch test strips (Lifescan; Johnson & Johnson
Co.). Animals that tested positive for hyperglycemia on two con-
secutive occasions 48 h apart were deemed diabetic.
Results
TNF-a Enhances Effector Activity of Both CD41 and CD81
Islet-specific T Cells. Our prior work showed that islet-
specific expression of TNF-a in neonatal NOD mice pro-
motes rapid onset of diabetes (29). In part, this was related
to the ability of TNF-a to recruit APCs, particularly DCs
and MFs, to neonatal islets and promote presentation of is-
let antigen to T cells. However, whether TNF-a–mediated
APC activation enhanced activity of CD41 or CD81 T cells
was unknown (29). In this study, we first addressed this is-
sue by adoptively transferring BDC2.5 CD41 TCR-trans-
genic T cells (31) or CD81 T cell clone TGNFC8 (32), into
TNF-a–scid/scid mice and monitored diabetes development.
As controls, we transferred the cells into nontransgenic
(non-tg) NOD–scid/scid littermates.
Transfer of splenocytes from 6-wk-old BDC2.5 CD41
TCR-transgenic donor mice into TNF-a–scid/scid recipi-
ents resulted in diabetes as early as 48 h after transfer (Table
II). By 72 h, all recipient mice were diabetic. In contrast,
transfer of BDC2.5 CD41 TCR-transgenic T cells into
control non-tg NOD–scid/scid mice did not induce diabe-
tes before 1 wk after transfer, generally taking 9 d to induce
disease. TNF-a–scid/scid mice or non-tg NOD–scid/scid
mice that did not receive the CD41 T cells never devel-
oped diabetes.
Similar findings occurred when CD81 TGNFC8 cells
were transferred into TNF-a–scid/scid recipients, diabetes
being detectable 48 h after transfer. However, transfer of
CD81 TGNFC8 cells into control non-tg NOD–scid/scid
mice did not induce disease until 1 wk after transfer (Table
II). Verification of b cell destruction was established by his-
tological examination for insulin-producing cells in ex-
tracted pancreata from diabetic mice (not shown). Thus,
TNF-a expression in neonatal islets enhances effector
function of both activated CD41 and CD81 T cells.
CD81 T Cells Are Necessary for TNF-a–mediated Progres-
sion to Diabetes in NOD Mice. We further investigated the
role of CD81 and CD41 T cells in the progression to dia-
betes in TNF-a–NOD mice by using a series of knockout
models (Table I). First, we addressed the role of CD81 T
cells. For this, we crossed TNF-a–NOD mice to NOD
mice bearing a null mutation for b2-microglobulin (b2m2/2).
Such mice do not express MHC class I molecules, lack
CD81 T cells due to defective thymic positive selection,
and do not develop insulitis or diabetes (Table I). We mon-
itored TNF-a–b2m1/1, TNF-a–b2m2/1, and TNF-a–b2m2/2
mice for progression to diabetes.
As shown in Fig. 1 a, neither male nor female TNF-a–
b2m
2/2 mice developed diabetes over a 30-wk observation
period. In contrast, TNF-a–b2m1/1 littermates developed
diabetes with 100% incidence by 14 wk of age in both
males and females. TNF-a–b2m1/2 mice also developed dia-
betes, although the kinetics of the disease were slightly re-
tarded, with 100% incidence of disease occurring by 20 wk
of age in both sexes. Thus, CD81 T cells are required for
TNF-a–mediated diabetes in NOD mice. To confirm that b
cell destruction required specific stimulation of CD81 T cells
via their TCRs, as a control we transferred the TGNFC8
clone into 6-wk-old TNF-a–b2m1/1, TNF-a–b2m2/2, or
non-tg NOD–b2m2/2 mice. Only TNF-a–b2m1/1 devel-
oped diabetes over a 6-wk observation period (not shown).
Protection Against Diabetes in TNF-a–b2m2/2 Mice Is Not
Related to Blockade of Insulitis. NOD–b2m2/2 mice and NOD
mice treated neonatally with anti-CD8 antibodies are pro-
tected from diabetes because they fail to develop insulitis
(18–20). To determine whether insulitis blockade in TNF-
a–b2m2/2 mice was responsible for protection against dia-
betes, we performed histologic studies of the pancreas of
15- and 42-d-old TNF-a–b2m2/2 mice or age-matched
control TNF-a–b2m1/1 mice.
At 15 d of age, both TNF-a–b2m1/1 and TNF-a–b2m2/2
mice had similar islet infiltrates composed of DCs, B cells, and
some CD41 T cells, which shows that TNF-a can bypass the
need for MHC class I molecules for the initiation of insulitis
(not shown; reference 33). In contrast, at 42 d of age there
were distinct differences in T cells and DCs that infiltrated the
islets of TNF-a–b2m1/1 and TNF-a–b2m2/2 mice. First, as
expected, CD81 T cells were detectable only in islets
Table II. TNF-a Promotes Autoaggression of Islet-specific T Cells
Donor/cell source Recipient
Days after transfer
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
TGNFC9 NOD–scid/scid 0 0 0 0 0 0 3 3 3 3 3 3 3 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
TNF-a–NOD–scid/scid 0 4 6
BDC2.5 NOD–scid/scid 0 0 0 0 0 0 0 0 2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
TNF-a–NOD–scid/scid 0 2 6
107 cloned CD81 T cells (TGFNC8) or 107 splenocytes from BDC2.5 CD41 TCR-transgenic mice were transferred into 6-wk-old female TNF-
a–scid/scid (n 5 6) or non-tg scid/scid littermates (n 5 6). Diabetes progression was monitored until 28 d after transfer.
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from TNF-a–b2m1/1 mice (not shown). Second, in TNF-
a–b2m1/1 mice, there was a significant increase in CD11c1
CD11b2 DCs infiltrating the islets, whereas in TNF-a–b2m2/2
mice, CD11c1CD11b1 DCs predominated. This latter find-
ing was confirmed by FACS® analysis of islet-infiltrating cells
from 42-d-old TNF-a–b2m1/1 and TNF-a–b2m2/2 mice
(Fig. 2 b). This difference in DC populations in the islets be-
tween the two groups of mice was not due to a general ab-
sence of CD11c1CD11b2 DCs in TNF-a–b2m2/2 mice, as
CD11c1CD11b2 DCs were clearly detectable in the spleens
of TNF-a–b2m2/2 mice. Similar histological or FACS® anal-
ysis of CD41 T and B cells detected no differences between
TNF-a–b2m1/1 and TNF-a–b2m2/2 mice.
This data suggests that CD81 T cells are required for the
progression to diabetes in TNF-a–NOD mice and may also
be involved in the recruitment, expansion, or differentiation
of CD11c1CD11b2 DCs in TNF-a–NOD islets. The im-
portance of these emerging CD11c1CD11b2 DCs in the is-
lets of TNF-a–b2m1/1 mice is currently under investigation.
Priming of CD41 T Cells to Islet Antigen Is Unaffected in
TNF-a–b2m2/2 Mice. It has been suggested that CD81 T
cells are required for effective priming and expansion of au-
toreactive CD41 T cells in NOD mice (19). Thus, we
tested whether CD41 T cells in TNF-a–b2m2/2 mice were
efficiently primed to islet antigen. First, we asked whether
islet-infiltrating APCs from TNF-a–b2m2/2 could present
islet antigen to NOD T cells.
Islet-infiltrating APCs from 6-wk-old TNF-a–b2m1/1
and TNF-a–b2m2/2 mice were isolated and cultured with
purified CD41 or CD81 T cells from 6-wk-old NOD mice.
As shown in Fig. 1 c, islet-infiltrating APCs from TNF-a–
b2m
2/2 mice stimulated purified CD41 T cells as efficiently
as APCs extracted from the islets of TNF-a–b2m2/2 mice.
In contrast, only islet-infiltrating APCs from TNF-a–b2m1/1
mice stimulated purified CD81 T cells, as expected.
Next, we tested the reactivity of purified CD41 T cells
from TNF-a–b2m2/2 mice or TNF-a–b2m1/1 mice to
GADp35, a prominent diabetogenic peptide from glutamic
acid decarboxylase GAD. Previous reports have speculated
that the generation of GAD-reactive CD41 T cells is a pre-
requisite for the generation of other antiislet responses (34,
35). As a comparison, we also assayed purified CD41 T
cells from non-tg NOD–b2m2/2 mice. In all cases, anti-
GADp35 responses were clearly detectable, with CD41 T
cells from TNF-a–b2m2/2 mice in fact generating the
strongest responses (Fig. 1 d).
Figure 1. CD81 T cells are required for diabetes
development in TNF-a–NOD mice. (a) Graphical
representation of diabetes progression in pooled
male and female TNF-a–b2m1/1 (h; n 5 25),
TNF-a–b2m1/2 (d; n 5 21), and TNF-a–b2m2/2
(s; n 5 26) mice. (b) CD11c1CD11b1 DCs pre-
dominate over CD11c1CD11b2 DCs in the islets
of adult TNF-a–b2m2/2 mice. Islet-infiltrating
cells or splenocytes from 6-wk-old TNF-a–b2m1/1
or TNF-a–b2m2/2 mice were incubated with
anti-CD3, -CD11c, -CD11b, and -CD45 anti-
bodies. The percentage of CD11b1 and CD11b2
DCs in the CD451CD32CD11c1 fraction was de-
termined by FACS®. The data is representative of
eight individual animals. (c) Islet-infiltrating APCs
from TNF-a–b2m2/2 mice efficiently present islet
antigen to NOD CD41 T cells. Islet-infiltrating
cells were isolated from 6-wk-old TNF-a–b2m1/1
or TNF-a–b2m2/2 mice, and 5 3 104 irradiated
cells were cultured with 105 purified CD41 or
CD81 T cells from 6-wk-old NOD mice. After a
16-h pulse with 1 mCi of [3H]thymidine on the
last day of a 4-d culture, proliferative responses
were measured. The assay was performed in tripli-
cate and the data presented as mean counts per
minute (cpm) 6 SD. Background cpm for CD41
and CD81 T cells cultured in medium alone was
,500. (d) CD41 T cells from TNF-a–b2m2/2
mice are primed to GADp35. 5 3 105 purified
CD41 T cells from 6-wk-old TNF-a–b2m1/1
(h), TNF-a–b2m2/2 (r), or non-tg NOD–b2m2/2
mice (j) were stimulated with GADp35 at the
concentrations shown, using 5 3 105 irradiated
splenocytes from 6-wk-old NOD mice as a source
of APCs. After 4 d of culture, proliferative re-
sponses were measured as before. The assay was
performed in triplicate and the data presented as
mean cpm 6 SD. Background cpm for CD41 T
cells cultured with APCs alone was ,400.
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These findings show that CD41 T cells in TNF-a–b2m2/2
mice can be efficiently primed to islet antigen in the ab-
sence of CD81 T cells. Furthermore, the generation of
islet-reactive CD41 T cells is not sufficient to induce dia-
betes in this TNF-a model. Instead, diabetes progression
requires CD81 T cells, perhaps acting through cytolytic at-
tack on the b cells.
TNF-a Bypasses the Need for MHC Class II Signaling to In-
duce Diabetes in NOD Mice. The generation of cytotoxic
CD81 T cells normally requires CD41 T cell help (1). We
decided to test whether CD41 T cell help was a prerequi-
site for progression to diabetes in our TNF-a model. To
address this, we crossed TNF-a–NOD mice to NOD mice
that do not express MHC class II molecules on their APCs.
NOD–CIITA2/2 mice, which carry a null mutation for
the CIITA molecule, provide a good model system to ad-
dress this issue (21).
CIITA (36) is a key factor involved in the expression of
MHC class II molecules as well as the upregulation of MHC
class I molecules by IFN-g (37–43). As such, CIITA2/2
mice do not express MHC class II on the majority of their
APCs and exhibit the same reduction in peripheral CD41
T cell numbers as MHC class II–deficient mice (44, 45).
Recently, we showed that NOD–CIITA2/2 mice have
significant pancreatic infiltration but do not develop diabe-
tes due to CD41 T cell deficiency (21).
Comparative analysis of TNF-a–CIITA2/2 and TNF-
a–CIITA1/1 mice revealed no distinct differences in the ki-
netics or penetrance of diabetes (Fig. 2 a). In both groups of
mice, diabetes started at 10 wk of age, with males and females
showing 100% incidence of diabetes by 15 wk of age. In con-
trast, NOD–CIITA2/2 mice never progressed to diabetes
over a 50-wk observation period (21). Heterozygous TNF-
a–CIITA2/1 mice also developed diabetes, albeit with slightly
slower kinetics. Thus, islet-specific expression of TNF-a in
NOD–CIITA2/2 mice restores their susceptibility to diabetes.
Figure 2. TNF-a promotes diabetes in NOD–CIITA2/2 mice. (a) Graphical representation of diabetes devel-
opment in pooled male and female TNF-a–CIITA1/1 (h; n 5 22), TNF-a–CIITA1/2 (d; n 5 16), and TNF-
a–CIITA2/2 (s; n 5 26) mice. (b) Islet-infiltrating DCs in TNF-a–CIITA2/2 mice are MHC class IIloCD86hi.
Islet-infiltrating cells from 5-wk-old TNF-a–CIITA1/1 and TNF-a–CIITA2/2 littermates were incubated with
anti-CD3, -CD11c, -CD11b, -B220, –I-Ad, and -CD86 antibodies. The percentages of cells expressing MHC
class II I-Ad (top) and CD86 costimulatory molecules (bottom) on CD32CD11c1CD11b2 DCs, CD32CD11c1
CD11b1 DCs, CD32CD11c2CD11b1 MFs, and CD32B2201 B cells were determined by FACS®. (c) Islet-infil-
trating APCs in TNF-a–CIITA2/2 mice are inefficient presenters of islet antigen to NOD CD41 T cells. 5 3 104
irradiated islet-infiltrating cells from 5-wk-old TNF-a–CIITA1/1 and TNF-a–CIITA2/2 littermates were incu-
bated with 105 purified CD41 T cells from 6-wk-old NOD mice, and the proliferative responses of triplicate cul-
tures were measured as before. Background cpm for CD41 T cells cultured in medium alone was ,550. Stimula-
tion indices were calculated as the fold-increase in response of CD41 T cells against background cpm and are
shown above the bars. (d) GAD-specific CD41 T cells are absent in TNF-a–CIITA2/2 mice. Purified CD41 T
cells (3 3 105), isolated from the pancreatic lymph nodes of 6-wk-old TNF-a–CIITA1/1 (j), TNF-a–CIITA2/2
(r), or non-tg NOD–CIITA2/2 (s) mice, were incubated with 5 3 105 irradiated splenocytes and 0–20 mg/ml
of GADp35. After a 4-d culture, proliferative responses of triplicate cultures were measured. Background cpm for
CD41 T cells was ,450.
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APCs in the Islets of TNF-a–CIITA2/2 Mice Are Defective
in Priming CD41 T Cells to Islet Antigen. A recent report
by Williams et al. (46) demonstrated that DCs in CIITA2/2
mice express MHC class II, although this was restricted to
CD11c1 DCs extracted from the inguinal lymph nodes. It
was therefore possible that diabetes development in TNF-
a–CIITA2/2 mice could occur because MHC class II–
expressing DCs activated the few CD41 T cells present in
these mice to provide help for CD81 T cells. To address
these issues, we performed FACS® and functional analysis.
First, we extracted islet-infiltrating APCs from 5-wk-old
TNF-a–CIITA1/1 or TNF-a–CIITA2/2 mice and com-
pared expression levels of MHC class II on DCs, MFs, and
B cells by FACS® analysis. As shown in Fig. 2 b, 45% of
islet-infiltrating CD11c1CD11b2 and CD11c1CD11b1
DCs in TNF-a–CIITA2/2 mice expressed MHC class II
molecules, but at very low levels. Very few MFs and B
cells expressed MHC class II (9 and 14%, respectively). Ex-
pression levels of MHC class II were z100-fold less than
those on islet-derived APCs from TNF-a–CIITA1/1 mice.
We next performed functional experiments to determine
if these MHC class IIlo APCs from TNF-a–CIITA2/2
mice could present islet antigen to CD41 T cells from
NOD mice. The islet-infiltrating APCs from 5-wk-old
TNF-a–CIITA1/1 or TNF-a–CIITA2/2 mice were cul-
tured with purified NOD CD41 T cells, and the stimula-
tory capacity of the respective APCs was assessed.
APCs from the islets of TNF-a–CIITA1/1 were highly
efficient at stimulating purified CD41 T cells, inducing a
47-fold increase in response of CD41 T cells cultured in
the presence of medium alone (Fig. 2 c). In contrast, APCs
extracted from the islets of TNF-a–CIITA2/2 mice were
poor stimulators of CD41 T cells, inducing only a fivefold
increase in response above background levels of CD41 T
cells alone. This inability of APCs from TNF-a–CIITA2/2
mice to stimulate CD41 T cells was not due to a defect
in the maturation of DCs in the islets of these mice. In-
deed, FACS® analysis confirmed that DCs from TNF-a–
CIITA1/1 and TNF-a–CIITA2/2 mice expressed identical
high levels of costimulatory molecule CD86, which is a
marker for mature DCs (Fig. 2 b). To further examine the
MHC class II–dependent activation of CD41 T cells in
TNF-a–CIITA2/2 mice, we compared the GADp35 re-
sponses of purified CD41 T cells from TNF-a–CIITA1/1
versus TNF-a–CIITA2/2 mice. As shown in Fig. 2 d, only
CD41 T cells from TNF-a–CIITA1/1 mice were effi-
ciently primed to the autoantigen.
Together, these findings demonstrate that TNF-a can
promote diabetes in NOD–CIITA2/2 mice that have se-
verely reduced numbers of islet-reactive CD41 T cells, is-
let-infiltrating APCs incapable of presenting islet antigen to
CD41 T cells, and defective CD41 T cell responses to dia-
betogenic antigens. Nevertheless, we cannot exclude the
possibility that TNF-a synergizes with the minimal help
provided by the few CD4 T cells in conjunction with the
MHC class IIlo DCs to promote CD81 T cell responses.
TNF-a Promotes Diabetes in NOD Mice Independent of
CD154 Signals. Interaction of CD154 on CD41 T cells
and CD40 on immature DCs initiates maturation of DCs
and enhances their ability to activate both CD41 and CD81
T cells (5). Indeed, the requirement for CD41 T cell help in
the priming of CD81 T cells by DCs can be bypassed if DCs
are activated by cross-linking CD40 (2–4).
We determined whether TNF-a, in a way analogous to
a viral infection, could induce signaling through a CD40–
CD154-independent pathway and induce the activation of
CD81 T cells. First, we generated NOD–CD154-deficient
(NOD–CD1542/2) mice by backcrossing our previously
described C57BL/6 CD1542/2 mice (47) to NOD for 11
generations and then intercrossing heterozygous progeny.
NOD–CD1542/2 mice failed to develop insulitis and, as a
consequence, were protected from diabetes. These findings
are consistent with previous reports using anti-CD154 anti-
bodies (14).
We then crossed TNF-a–NOD mice (N11) with non-tg
NOD–CD1542/2 mice (N11) and monitored diabetes
progression in TNF-a–CD1541/1, TNF-a–CD1542/2,
and non-tg NOD–CD1542/2 littermates. Both TNF-a–
Figure 3. TNF-a promotes diabetes in NOD–CD1542/2 mice. (a) Graphical representation of diabetes progression in pooled male and female TNF-
a–CD1541/1 (s; n 5 25), TNF-a–CD1542/2 (r; n 5 20), and non-tg NOD–CD1542/2 (h; n 5 15) mice. (b) Islet-infiltrating APCs from TNF-
a–CD1542/2 mice can stimulate islet-specific T cells. Irradiated islet-infiltrating cells (5 3 104) from 5-wk-old TNF-a–CD1541/1 or TNF-a–CD1542/2
mice were incubated with 105 purified CD41 or CD81 T cells (left and right panels, respectively) from 6-wk-old NOD mice and proliferative responses
for triplicate cultures were determined as before. Background cpm was ,500 for CD41 T cells and ,300 for CD81 T cells.
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CD1541/1 and TNF-a–CD1542/2 mice developed diabe-
tes with almost identical kinetics (Fig. 3 a); the penetrance of
disease was essentially 100% in both sexes by 15 wk of age.
In contrast, non-tg NOD–CD1542/2 mice never developed
disease over the 30-wk observation period.
Histological examination of the islets from 15- and 42-
d-old TNF-a–CD1541/1 and TNF-a–CD1542/2 mice re-
vealed no obvious differences in the kinetics of insulitis.
Nor could we detect any differences in the phenotype of
infiltrating cells or their intraislet localization between the
two groups of mice (not shown). In contrast, similar analy-
sis of non-tg NOD–CD1542/2 mice revealed no evidence
of insulitis (not shown). Thus, TNF-a can bypass the need
for CD40–CD154 signals for insulitis and diabetes in NOD
mice.
The Inflammatory Environment Created by TNF-a Can Bypass
CD154 Signals to Activate Islet-infiltrating APCs. As TNF-
a–CD1542/2 mice developed diabetes with kinetics similar
to those of TNF-a–CD1541/1 mice, we tested whether
TNF-a enhanced the presentation of islet antigen to CD41
and/or CD81 T cells by APCs from these mice. Islet-infil-
trating APCs were extracted from 5-wk-old TNF-a–
CD1541/1 or TNF-a–CD1542/2 mice and cultured with
either purified CD41 or CD81 T cells from 6-wk-old NOD
mice. As shown in Fig. 3 b, islet-infiltrating APCs freshly
isolated from TNF-a–CD1542/2 mice stimulated CD41
and CD81 T cells as efficiently as APCs isolated from the
islets of TNF-a–CD1541/1 mice. Indeed, proliferative re-
sponses for both responder cells were slightly higher after
culture with TNF-a–CD1542/2 islet-extracted APCs.
Thus, TNF-a can promote activation of islet-infiltrating
APCs in the absence of CD40–CD154 signals, and these
APCs are potent presenters of islet antigen to autoreactive
T cells.
CD41 T Cell Responses Are Defective in TNF-a–
CD1542/2 Mice. We next tested whether CD41 T cells in
TNF-a–CD1542/2 mice were primed to islet antigen.
Purified CD41 T cells were isolated from the pancreatic
lymph nodes of 6-wk-old TNF-a–CD1541/1 or TNF-a–
CD1542/2 mice, and their responses to GADp35 were
measured in vitro. As a comparison, we included purified
CD41 T cells from non-tg NOD–CD1542/2 littermates.
Neither CD41 T cells from TNF-a–CD1542/2 mice
nor non-tg NOD–CD1542/2 mice responded to GADp35,
which contrasted significantly to the vigorous response by
CD41 T cells from TNF-a–CD1541/1 mice (Fig. 4 a). To
confirm that this lack of response in the latter two groups
of mice did not relate to the GAD peptide used, we re-
peated the experiments with whole GAD protein. Similar
to the above findings, only CD41 T cells from TNF-a–
CD1541/1 mice responded to GAD (not shown).
The generation of GAD-specific responses is dependent
on the efficient presentation of GAD by B cells (48). There
has been some suggestion in studies with CD1542/2 or
CD402/2 mice that efficient B cell function is dependent
on CD154–CD40 signals, whereas these signals can be by-
passed for DC activation after viral infections (49–53).
Thus, it was possible that the poor response to GAD in
TNF-a–CD1542/2 mice simply reflected a defect in B cell
presentation. To test this, we assessed whether CD41 T
cells from TNF-a–CD1542/2 mice could respond to other
islet antigens. CD41 T cells were purified from 6-wk-old
TNF-a–CD1542/2 or age-matched control NOD mice and
then incubated with islet-infiltrating APCs from either
TNF-a–CD1541/1 or TNF-a–CD1542/2 mice. CD41 T
cells from TNF-a–CD1542/2 mice responded poorly to
islet antigen irrespective of whether the antigen was pre-
sented by TNF-a–CD1541/1 or TNF-a–CD1542/2 islet-
Figure 4. TNF-a–CD1542/2 mice cannot mount GAD-specific CD41 T cell responses. (a) CD41 T cells were purified from the pancreatic lymph
nodes of 6-wk-old TNF-a–CD1541/1 (r), TNF-a–CD1542/2 (s), or non-tg NOD–CD1542/2 (m) mice and cultured with 5 3 105 irradiated sple-
nocytes from 5-wk-old NOD mice and 0–20 mg of GADp35. After a 4-d culture, proliferative responses of triplicate cultures were determined. Back-
ground cpm for CD41 T cells cultured with irradiated splenocytes was ,500. (b) CD41 T cells from TNF-a–CD1542/2 mice show decreased responses
to islet antigen. Left, irradiated islet-infiltrating cells (3 3 104) from 6-wk-old TNF-a–CD1541/1 or TNF-a–CD1542/2 mice were cultured with 2 3
106 CD41 T cells purified from 6-wk-old TNF-a–CD1542/2 mice or age-matched control NOD mice. Proliferative responses of triplicate cultures
were measured after 4 d as described previously. Background cpm for CD41 T cells was ,520. Right, islet-infiltrating cells from 6-wk-old TNF-a–
CD1541/1 or TNF-a–CD1542/2 mice were depleted of CD81 T cells, and the remaining cells were cultured with 2.5 mg/ml of Con A for 48 h. Cul-
ture supernatants were harvested at the end of the incubation period, and IFN-g was detected by ELISA. The ELISA assay was performed in triplicate
and the data presented as mean 6 SD. (c) CD41 T cells in TNF-a–CD1542/2 mice cannot be primed to exogenous protein antigens. Groups of two
6-wk-old TNF-a–CD1541/1 (r), TNF-a–CD1542/2 (m), non-tg NOD–CD1541/1 (j), and non-tg NOD–CD1542/2 (d) mice were immunized
subcutaneously via their footpads with 100 mg of KLH in alum. 7 d later, 5 3 105 cells isolated from the popliteal lymph nodes were cultured with KLH
at the concentrations (conc.) shown. After a 4-d incubation, proliferative responses of duplicate cultures were measured as before. Background cpm val-
ues for cells cultured in medium alone have been subtracted from the data.
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infiltrating APCs (Fig. 4 b). The response was three- to
fourfold less than that seen for NOD CD41 T cells stimu-
lated with the same islet-derived APCs. Further evidence
that CD41 T cells in TNF-a–CD1542/2 mice were ineffi-
ciently primed to islet antigen was suggested by the fact that
CD41 T cells infiltrating the islets of TNF-a–CD1542/2
mice failed to differentiate into effector Th1 or Th2 cells
(Fig. 4 c). Indeed, z250 U/ml of IFN-g was detectable in
culture supernatants after stimulation of CD81 cell–
depleted, islet-infiltrating cells from TNF-a–CD1541/1 mice
with Con A for 48 h. In contrast, ,50 U/ml of IFN-g was
detected after Con A stimulation of CD81 T cell–depleted,
islet-infiltrating cells from TNF-a–CD1542/2 mice. This
reduced ability of TNF-a–CD1542/2 islet-derived CD41
T cells to produce IFN-g was not due to a defect in their
capacity to respond to Con A, as both CD41 T cells from
TNF-a–CD1541/1 and TNF-a–CD1542/2 mice prolif-
erated equally well (not shown). Nor was it related to
skewing of the CD41 T cells to a Th2 phenotype, as we
could detect no IL-4 production by CD41 T cells from ei-
ther TNF-a–CD1541/1 or TNF-a–CD1542/2 mice (not
shown).
Finally, to establish whether the defect in CD41 T cell re-
sponses in TNF-a–CD1542/2 mice was specific for islet-
derived antigens, we measured recall responses of CD41 T
cells from TNF-a–CD1542/2 mice to the exogenous pro-
tein antigen KLH after primary immunization. 7 d after im-
munization with KLH, popliteal lymph nodes were removed
from TNF-a–CD1541/1 and TNF-a–CD1542/2 mice, and
anti-KLH responses were monitored. As controls, non-tg
NOD–CD1541/1 and non-tg NOD–CD1542/2 mice were
included in the assay. As shown in Fig. 4 c, CD41 T cells
from both TNF-a–CD1542/2 and non-tg NOD–CD1542/2
had diminished capacity to respond to KLH in comparison
to the response seen for CD41 T cells isolated from TNF-a–
CD1541/1 and non-tg NOD–CD1541/1 mice. Thus, CD41
T cell responses are universally defective in NOD–CD1542/2
mice and, islet-specific expression of TNF-a cannot over-
come this defect.
CD81 T Cell Responses Are Intact in TNF-a–CD1542/2
Mice. As priming of CD41 T cells to antigens was defec-
tive in TNF-a–CD1542/2 mice, it was important to estab-
lish whether CD81 T cell responses to islet antigen were
also affected. We had already established that the APCs
infiltrating the islets of TNF-a–CD1542/2 mice could
present antigen to NOD CD81 T cells as efficiently as
APCs derived from the islets of TNF-a–CD1541/1 mice
(Fig. 3 b). To determine whether this led to priming of
CD8 T cell responses in vivo, we measured the ability of
CD81 T cells from 6-wk-old TNF-a–CD1542/2 mice to
respond to islet antigen presented by islet-infiltrating APCs
from 6-wk-old TNF-a–CD1542/2 or TNF-a–CD1541/1
mice (Fig. 5 a). As a control, we included CD81 T cells
from age-matched NOD mice as responders in the assay.
There was no difference in the response of CD81 T cells
from TNF-a–CD1542/2 mice stimulated with islet-infil-
trating APCs from TNF-a–CD1542/2 or TNF-a–CD1541/1
mice (Fig. 5 a). Importantly, the response was as potent as
the response of NOD CD81 T cells stimulated with the
same respective APCs.
Next, we examined the effector status of the CD81 T
cells in the islets of 5-wk-old TNF-a–CD1542/2 mice by
analyzing the percentage of CD81 T cells that stained posi-
tive for perforin compared with the number of perforin-
positive CD81 T cells in the spleen. As a control, we also
assayed for perforin-positive CD81 T cells in the islets and
spleens of 8-wk-old TNF-a–CD1541/1 mice. FACS®
analysis demonstrated that z60% of the CD81 T cells in
the islets of TNF-a–CD1542/2 mice stained positive for
perforin, a strikingly high number, as only 18% of the
CD81 T cells in the spleens of these mice were perforin
positive (Fig. 5 b). These respective values were even
higher than the percentage of CD81 perforin-positive T
cells detected in TNF-a–CD1541/1 islets and spleens (36
Figure 5. CD81 T cell responses are not impaired in TNF-a–
CD1542/2 mice. (a) Islet-infiltrating cells (3 3 104) from 6-wk-old TNF-
a–CD1541/1 or TNF-a–CD1542/2 mice were cultured with 2 3 105
purified CD81 T cells from 6-wk-old TNF-a–CD1542/2 mice or age-
matched control NOD mice. Proliferative responses of triplicate cultures
after a 4-d culture were determined as before. Background cpm for
CD81 T cells was ,400. (b) Effector CD81 T cells are present in the is-
lets of TNF-a–CD1542/2 mice. Islet-infiltrating cells from 5-wk-old
TNF-a–CD1542/2 or control 8-wk-old TNF-a–CD1541/1 mice were
incubated with anti-CD45, -CD8, and -CD3 antibodies. After fixation
and permeabilization, intracellular levels of perforin in the CD451
CD31CD81 population were determined by FACS® using an antiper-
forin antibody.
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and 7.5%, respectively). Whether this difference in perforin
levels between the two groups of mice relates to differences
in the age of the mice is unknown. In any event, these data
clearly demonstrate that CD81 T cell responses in TNF-a–
CD1542/2 mice are unaffected by the absence of CD154
and that effector CD81 T cells can be generated in the
presence of functionally defective CD41 T cells.
Discussion
In the periphery, activation of self-reactive CD81 T cells
usually involves cross-presentation of exogenous self-anti-
gen by APCs bearing MHC self-peptides. Such cross-pre-
sentation normally induces expansion followed by deletion
of self-reactive CD81 T cells (25, 54). Breakdown in toler-
ization of self-reactive CD81 T cells can lead to autoim-
munity. It is unclear what governs whether APCs promote
expansion and survival of activated self-reactive CD81 T
cells or their expansion followed by deletion.
Inflammatory cytokines have been implicated in the
breakdown of tolerance to self-antigens, yet the mecha-
nisms by which these mediators lead to inappropriate acti-
vation of T cells remains elusive (26). Recently, we dem-
onstrated that transgenic expression of TNF-a in the islets
of neonatal NOD mice promoted diabetes progression by
enhancing DC presentation of islet antigen to T cells in situ
(29). In this study, we demonstrated the potency of DC
presentation of islet antigen to CD41 and CD81 T cells for
the progression to diabetes in our TNF-a model. We
showed that adoptive transfer of splenocytes from BDC2.5
CD41 TCR-transgenic mice or the CD81 T cell clone,
TGNFC8, into TNF-a–scid/scid mice (which have exten-
sive DC infiltration in their islets) caused diabetes in all
recipients within 72 h after transfer, about two to three
times more rapidly than in non-tg scid/scid controls. Al-
though this transfer study showed that the inflammatory
environment created by TNF-a enhanced autoaggression
of previously activated islet-specific CD41 and CD81 T
cells, it did not reveal whether diabetes development in
TNF-a–NOD mice was dependent on CD41 and/or
CD81 T cells. We first addressed this issue by examining
the requirement for CD81 T cells. Using the well charac-
terized NOD–b2m2/2 mice, we demonstrated that TNF-a
did not induce diabetes in the absence of CD81 T cells,
suggesting that CD81 T cells were vital for diabetes devel-
opment in TNF-a–NOD mice. However, unlike NOD–
b2m
2/2 mice, protection against diabetes in TNF-a–b2m2/2
mice did not result from a block in insulitis (17). In fact,
recruitment to and activation of APCs in the islets of
TNF-a–b2m2/2 mice occurred in the absence of CD81 T
cells. This was evident by comparative FACS® analysis of
APCs infiltrating the islets of TNF-a–b2m1/1 and TNF-
a–b2m2/2 mice, where the number of cells carrying high
levels of MHC class II and CD86 was equivalent between
the two groups of mice (not shown). Furthermore, func-
tional assays demonstrated no difference in the potency of
islet-infiltrating APCs from TNF-a–b2m1/1 and TNF-a–
b2m
2/2 mice to stimulate CD41 T cells. This latter finding
suggested that priming of autoreactive CD41 T cells in
TNF-a–b2m2/2 mice should be unaffected by the absence
of CD81 T cells, and indeed we showed that CD41 T cell
responses to a major diabetogenic antigen, GAD (35), were
even more potent in TNF-a–b2m2/2 mice than in TNF-
a–b21/1 mice.
Although the above finding proved that priming of
CD41 T cells to islet antigen is not sufficient to induce dis-
ease in TNF-a–NOD mice, it did not eliminate the possi-
bility that CD41 T cells were essential for efficient activa-
tion of CD81 T cells. CD41 T cells might play a dual role
in progression to diabetes in TNF-a–NOD mice, first, by
enhancing the capacity of APCs to prime CD81 T cells
and second, by promoting CD81 T cell function via the
secretion of cytokines like IFN-g or IL-2 (1). Alternatively,
it was possible that the inflammatory environment created
by TNF-a could bypass the need for CD41 T cells by pro-
moting APC activation via a CD154–CD40-independent
pathway.
To address the role of CD41 T cells in diabetes progres-
sion in TNF-a–NOD mice, we monitored diabetes devel-
opment in mice deficient for either MHC class II or
CD154 molecules. The findings presented from these stud-
ies indicate that CD41 T cell help can indeed be bypassed
in TNF-a–NOD mice. This was first suggested by the ob-
servation that TNF-a–CIITA2/2 mice progressed to dia-
betes with kinetics and penetrance similar to TNF-a–
CIITA1/1 mice, despite an eightfold reduction in the
number of peripheral CD41 T cells due to an absence of
MHC class II. This finding contrasted remarkably with our
recent report that NOD–CIITA2/2 mice were protected
from developing diabetes due to a paucity of CD41 T cells
(21). Although DCs in the islets of TNF-a–CIITA2/2
mice did express MHC class II, the levels of expression
were so low that these APCs were unable to present anti-
gen to CD41 T cells. Thus, it is unlikely that CD41 T cells
are efficiently activated in TNF-a–CIITA2/2 mice and are
therefore incapable of providing help to CD81 T cells.
Nor does it seem likely that CD41 T cell help is needed
for the activation of APCs in TNF-a–NOD mice through
the CD154–CD40 pathway. First, TNF-a–CD1542/2
mice developed diabetes with similar efficacy to TNF-a–
CD1541/1 mice. Subsequent support for this hypothesis
was provide by comparative FACS® analysis of the matura-
tion status of freshly isolated islet-infiltrating APCs from
TNF-a–CD1542/2 and TNF-a–CD1541/1 mice, with
similarly high levels of MHC and costimulatory molecules
being detectable for both groups of mice. However, it was
the demonstration that APCs infiltrating the islets of TNF-
a–CD1541/1 and TNF-a–CD1542/2 mice were similarly
efficient at presenting islet antigen to CD41 and CD81 T
cells that provided the strongest evidence that the inflam-
matory environment created by TNF-a can promote APC
function in the absence of CD154–CD40 signals. In view
of this observation, it is interesting that responses of CD41
T cells from TNF-a–CD1542/2 mice to both islet-derived
and exogenous protein antigens are as impaired as CD41 T
cell responses in non-tg NOD–CD1542/2 mice. Indeed,
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CD41 T cells present in the islets of TNF-a–CD1542/2
mice failed to differentiate into either Th2 or Th1 effector
cells, which contrasted with the finding that Th1 cells pre-
dominated in the islets of age-matched TNF-a–CD1541/1
mice. Taken together, these findings suggest that CD41 T
cell activation is dependent on CD154 signals, whereas an
inflammatory environment can induce APC maturation in-
dependent of the CD154–CD40 pathway.
In contrast to the functional impairment of CD41 T cells
in TNF-a–CD1542/2 mice, CD81 T cell activation seems
to be unaffected by the absence of CD154 signals, as CD81
T cells from TNF-a–CD1541/1 and TNF-a–CD1542/2
mice responded equally well to islet antigen in vitro. Fur-
thermore, .60% of CD81 T cells present in the islets of
TNF-a–CD1542/2 mice stained positive for perforin, a
marker for CD81 effector T cell differentiation. These
findings suggest that the inflammatory environment created
by TNF-a can promote cross-presentation of exogenous
islet antigen by islet-infiltrating APCs to CD81 T cells in
the absence of CD41 T cell help, particularly CD154–
CD40 signals.
The CD154–CD40-independent molecular pathway
used for the activation of APCs in TNF-a–CD1542/2
mice is unknown. However, we and our colleagues have
shown previously that CD1542/2 mice on the C57BL/6
background can mount potent antiviral CD81 T cell re-
sponses (4, 50, 51, 53). In these instances, signaling be-
tween other members of the TNF and TNFR superfami-
lies, receptor activator of nuclear factor kB (RANK) on DCs
and TNF-related activation induced cytokine (TRANCE)
on T cells, can substitute for the absence of CD154 for ef-
ficient activation of CD81 T cells in these mice (49).
Whether the environment created by TNF-a indirectly
promotes signaling through the RANK–TRANCE path-
way or if TNF-a itself directly promotes APC maturation
via the TNFRs in TNF-a–CD1542/2 mice remains to be
established.
How can we correlate the findings presented here with
previous reports that islet-specific expression, or systemic
administration of TNF-a in adult NOD mice protects
against diabetes (55, 56)? TNF-a–mediated protection
against diabetes in these latter models is thought to be re-
lated to a downregulation of CD41 T cell responses to islet
antigens (57). However, this study shows that CD41 T cell
responses to islet antigens are not necessary for diabetes in
TNF-a–NOD mice. Thus, the differences in pathological
outcomes between neonatal and adult expression or sys-
temic administration of TNF-a may relate to specific inhi-
bition of islet-specific CD81 T cell responses in the latter
model. How TNF-a can regulate CD81 T cell responses
differently depending on the age of NOD mice is open to
speculation. It is possible that expression of TNF-a in adult
NOD mice enhances presentation of a unique set of pep-
tides that specifically tolerize CD81 T cells. Another possi-
bility is that the signal pathways triggered by the TNF-a–
mediated inflammatory environment in neonate versus
adult NOD mice are unique. For example, neonatal ex-
pression of TNF-a may inhibit signaling through CD30 on
islet-specific CD81 T cells, leading to their expansion and
activation (58). In adults, expression of TNF-a may indi-
rectly promote signaling through CD30, thereby prevent-
ing CD81 T cell responses to islet antigens (58). Future
studies analyzing the ability of TNF-a to manipulate the
signaling pathways involved in regulation of CD81 T cell
responses should clarify this issue.
Finally, how can we reconcile the findings presented in
this study with diabetes development in unmanipulated
NOD mice, and presumably humans? We hypothesize that
T cell priming to islet antigen in NOD mice also requires
cross-presentation of islet antigen. We suggest that apopto-
sis of b cells, a normal event that occurs in the remodeling
of the pancreas, releases islet antigens (59). These antigens
are acquired by scavenger APCs, which subsequently traffic
to the pancreatic lymph nodes, where they interact with
autoreactive CD41 T cells (60). This interaction induces
upregulation of CD154 on CD41 T cells and induces APC
activation by signaling through CD40, leading to the up-
regulation of MHC–peptide complexes and costimulatory
molecules on APCs. These mature APCs can then effi-
ciently cross-prime CD81 T cells to exogenous islet anti-
gen. Primed T cells then migrate to the islet and promote
activation of newly infiltrating APCs, which in turn pro-
mote secondary stimulation of the primed T cells. During
this secondary stimulation, CD154–CD40 signals are no
longer critical, as production of TNF-a in situ by activated
DCs/MFs (61) promotes CD154–CD40-independent ac-
tivation of CD81 T cells. Thus, in NOD mice, CD154–
CD40 signals will be critical only for the initiation phase of
diabetes (14). In TNF-a–NOD mice, CD154–CD40 sig-
nals are not necessary for either the initiation or effector
phases of diabetes, as the secretion of TNF-a in situ by
transgenic b cells recruits and activates APCs to present an-
tigens from apoptotic b cells to CD81 T cells in neonatal
islets.
In conclusion, our data suggests that neonatal expression
of TNF-a in NOD islets promotes cross-presentation of is-
let antigen to CD81 T cells using a unique CD154–CD40-
independent pathway. As tolerance of CD41 T cells to self-
antigen normally controls activation of self-reactive CD81
T cells, our data also indicate a mechanism by which in-
flammatory stimuli may precipitate autoimmunity even in
the presence of CD41 T cell tolerance.
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